卵巢癌风险预测模型在上皮性卵巢癌早期诊断中的应用价值

doi:10.13481/j.1671-587x.20190428

Abstract

Abstract: Objective:To investigate the value of risk ovarian malignancy algorithm (ROMA) in evaluation of the risk of epithelial ovarian cancer and its association with the clinical pathological stages, and to provide a basis for the clinical diagnosis and treatment and prognosis analysis of epithelial ovarian cancer. Methods:The clinical materials of 135 patients with ovarian tumor confirmed by paraffin section pathology after operation were retrospectively analyzed. The patients were divided into benign ovarian tumor group(n=66), epithelial ovarian cancer group(n=58) and non-epithelial ovarian cancer group(n=11).According to the cutoff values of HE4,CA125,and ROMA of the patients in various groups,the positive rates of HE4,CA125,and ROMA of the patients in various groups were calculated.Based on the serum levels of human epididymis protein 4(HE4) and carbohydrate antigen 125(CA125) detected before operation of the patients in various groups, the relationships between the positive rates of serum HE4, CA125 and ROMA and the clinical stages of the patients with ovarian cancer;their diagnosis efficacies in the patients with ovarian cancer were evaluated. Results:The serum CA125, HE4 levels and ROMA value of the patients in epithelial ovarian cancer group were significantly higher than those in benign ovarian tumor group and non-epithelial ovarian cancer group (P<0.05). The positive rates of HE4, CA125, and ROMA of the patients in epithelial ovarian cancer group were higher than those in benign ovarian tumor group (P<0.01), and showed an increasing trend with the increase of clinical stages.Compared with the positive rates of HE4 and CA125, the ROMA had the lowest positive rate in the patients with ovarian benign tumor, and the positive rates of ROMA in all stages of epithelial ovarian cancer were higher than those of CA125.The sensitivity and the negative predictive value of ROMA in postmenopausal patients with ovarian cancer group were higher than those in premenopausal patients with ovarian cancer group (P<0.05), while the specificity and the positive predictive value were not significantly different between premenopausal and postmenopausal patients with ovarian cancer groups (P>0.05). Among the three indexes, ROMA had the highest diagnostic efficacy index and CA125 had the lowest. Conclusion:The diagnostic value of ROMA for evaluating the risk of epithelial ovarian cancer was higher than those of CA125 and HE4, which has a better diagnostic value for the postmenopausal patients and can improve the early diagnosis efficiency of ovarian cancer.

Key words: carbohydrate antigen 125, human epididymis protein 4, ovarian neoplasms, Risk Ovarian Malignancy Algorithm, clinical diagnosis

CLC Number:

R737.31

WANG Yipin, HE Dongyun, HUANG Qiongwei, SHENG Minjia. Application value of risk ovarian malignancy algorithm in early diagnosis of epithelial ovarian cancer[J].Journal of Jilin University(Medicine Edition), 2019, 45(04): 905-910.

References

[1] PARYZHAK SIA, IAKUBETS' O I, VOROBETS Z D. Markers and regulatory mechanisms in ovarian carcinoma[J]. Ukr Biochem J, 2014,86(4):36-50.
[2] LU K H. Screening for ovarian cancer in asymptomatic women[J]. JAMA, 2018, 319(6):557-558.
[3] KUMARI S. Serum biomarker based algorithms in diagnosis of ovarian cancer:A review[J]. Indian J Clin Biochem, 2018,33(4):382-386.
[4] MOORE R G, MCMEEIN D S, BROWN A K, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2009,112(1):40-46.
[5] LYCKE M, KRISTJANSDOTTIR B, SUNDFELDT K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index[J]. Gynecol Oncol, 2018,151(1):159-165.
[6] CHAN K K, CHEN C A, NAM J H, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass[J]. Gynecol Oncol, 2013,128(2):239-244.
[7] ROMAGNOLO C, LEON A E, FABRICIO A S C, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass:An Italian multicenter study[J]. Gynecol Oncol, 2016,141(2):303-311.
[8] JEONG T D, CHO E J, KO D H, et al. A new strategy for calculating the risk of ovarian malignancy algorithm(ROMA)[J]. Clin Chem Lab Med, 2017,55(8):1209-1214.
[9] SANDRI M T, BOTTARI F, FRANCHI D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass:correlation with pathological outcome[J]. Gynecol Oncol, 2013,128(2):233-238.
[10] CRADIC K W, LASHO M A, ALGECIRAS-SCHIMNICH A. Validation of the cut-points recommended for ROMA using the roche elecsys CA125 and HE4 assays[J]. Ann Clin Lab Sci, 2018,48(1):90-93.
[11] HENDERSON J T, WEBBER E M, SAWAYA G F. Screening for ovarian cancer:updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2018,319(6):595-606.
[12] IONESCU C A, MATEI A, NAVOLAN D, et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses[J]. Medicine (Baltimore), 2018,97(31):e11762.
[13] YANG W L, ZHEN L, ROBERT C B. The role of biomarkers in the management of epithelial ovarian cancer[J]. Expert Rev Mol Diagn, 2017,17(6):577-591.
[14] WEI S, LI H, ZHANG B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer[J]. Biomed Rep, 2016,5(1):41-44.
[15] MOORE R G, MILLER M C, DISILVESTRO P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol, 2011,118(2 Pt 1):280-288.
[16] LIN J, QIN J, SANGVATANAKUL V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer:a systematic review and meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 167(1):81-85.
[17] ANTON C, CARVALHO F M, OLIVEIRA E I,et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses[J]. Clinics(Sao Paulo), 2012,67(5):437-441.
[18] SHEN F X, LU S M, PENG Y B, et al. Performance of ROMA based on Architect CA125Ⅱ and HE4 values in Chinese women presenting with a pelvic mass:A multicenter prospective study[J]. Clin Chim Acta, 2017,471:119-125.
[19] BANDIERA E, ROMANI C, SPECCHIA C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(12):2496-2506.
[20] DAYYANI F, UHLIG S, COLSON B, et al. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer:A meta-analysis[J]. Int J Gynecol Cancer, 2016,26(9):1586-1593.
[21] 冯艾,张琳,陈艳炯.不同绝经状态女性血清HE4、CA125和ROMA指数在卵巢癌诊断中的意义[J].西安交通大学学报:医学版,2018,39(1):78-83.
[22] MOLINA R,ESCUDERO J M,AUGÉ J M,et al. HE4:a novel tumour marker for ovarian cancer:comparison with CA125 and ROMA algorithm in patients with gynaecological diseases[J].Tumour Biol,2011,32(6):1087-1095.

Application value of risk ovarian malignancy algorithm in early diagnosis of epithelial ovarian cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIANG Bing, LIU Yang, SONG Jinping, QU Danhua, LIU Chunyan. Enhancement of histone deacetylase inhibitors SAHA in chemotherapeutic sensitivity of ovarian cancer SKOV3 cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 471-476.
[2]	SHANGGUAN Mengyuan, ZHAO Jing, YANG Yanrong, ZHANG Jiayue, CHEN Junyu, ZHAO Shuhua. Inhibitory effects of gomisin A combined with carboplatin on proliferation,invasion and metastasis of human ovarian cancer Skov3 cells and their mechanisms [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 292-298.
[3]	ZHONG Lili, ZHAO Yinlong, LI Bingjin, ZOU Xiaohan, CHENG Ziqian, CUI Ranji. Effects of MicroRNA-210 on growth and radiosensitivity of ovarian cancer cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 265-269.
[4]	SHANGGUAN Mengyuan, ZHAO Jing, CHEN Junyu, YANG Yanrong, ZHANG Jiayue, ZHAO Shuhua. Enhancement of gomisin A in pro-apoptotic effect of carboplatin on human ovarian cancer Skov3 cells and its mechanism [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 83-89.
[5]	WANG Xue, QIN Rui, WANG Haoying, GAO Shouyang, LAN Yanfang, TIAN Xiujuan. Inhititory effect of proliferation and promotion effect of apoptosis of lactacystin combined with carboplatin on ovarian cancer SKOV3 cells [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1098-1102.
[6]	LIN Yu, LIU Meihan, SHI Weidong, SUN Zhixia, CHEN Enqi, ZHANG Xin, WANG Zhiyuan. Application of ultrasonography in diagnosis and differential diagnosis of Takayasu arteritis [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1268-1271.
[7]	HE Dongyun, WANG Liyan, SHENG Minjia. Influence of prophylactic bilateral salpingectomy in ovarian function and its preventive effect on pelvic disease [J]. Journal of Jilin University Medicine Edition, 2017, 43(03): 635-639.
[8]	WANG Liyan, ZHANG Beibei, HE Dongyun, SHENG Minjia, WANG Xue. Influence of metformin and paclitaxel in proliferation and apoptosis of ovarian cancer SKOV3 cells in vitro [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 255-259.
[9]	WANG Haijiao, FAN Yanyan, ZHANG Shi, ZHANG Ruili, ZHANG Haijing, HAN Yahui, ZHU Jihong. Inhibitory effect of γδT cells on proliferation of ovarian cancer SKOV3 cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 897-900.
[10]	SHENG Minjia, LIU Jin, LIU Junbao, ZOU Jiyan. Effect of melatonin combined with carboplatin on proliferation and apoptosis of ovarian cancer SKOV3 cells in vitro [J]. Journal of Jilin University Medicine Edition, 2016, 42(01): 70-75.
[11]	WANG Kun, ZHANG Aichen, SHENG Minjia, PAN Ying, TONG Lingling, SUN Xiaochun. Expressions of OPN and CXCR4 in human epithelial ovarian cancer tissueand their clinical significances [J]. Journal of Jilin University Medicine Edition, 2015, 41(06): 1186-1189.
[12]	WU Shuang,LIU Yi-meng,LIU Chao,GUO Lin,XIAO Jian-ying. Detection of expressions of Ck2α,β-catenin and survivin in ovarian cancer tissue and its clinical application value [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1256-1260.
[13]	ZHAO Li-hua,WANG Xue,CAO Lu,TIAN Xiu-juan,LIU Hui . Expression of osteopontin in human epithelial  ovarian carcinoma tissue and its significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 154-158.
[14]	LIU Yang1,NI Jin-song2,ZHANG Xiao-xia1,ZHANG Hai-peng1,HAN Bing3. Expression of B7-H4 protein in ovarian epithelial tumor tissue and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2013, 39(4): 777-.
[15]	LV Chang-shuai\|ZHANG You-zhong\|DING Bai-juan\|JIANG Kan\|LIU Hong-li. Effects of TMPyP4-PDT on human ovarian carcinoma A2780 cells in vitro and expressions of MCM2 and CA-Ⅸ \|mRNA [J]. J4, 2012, 38(5): 850-855.